Aztreonam/avibactam?

Aztreonam/Avibactam
(commercially marketed as Aztreonam/Avibactam or “AZT‑AVA” in some regions)

---

1. What is it?

Component	Class	Mechanism of action	Key properties
Aztreonam	Monobactam β‑lactam antibiotic	Inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins (PBPs); highly selective for Gram‑negative rods.	Stable against most β‑lactamases (including carbapenemases); ineffective against β‑lactamase‑producing Gram‑positive bacteria.
Avibactam	Non‑β‑lactam β‑lactamase inhibitor	Reversibly binds to a wide range of serine β‑lactamases (including KPC, AmpC, OXA‑48‑like, NDM‑1, etc.).	Non‑β‑lactam core → no cross‑reactivity with penicillin allergy; reversible binding; long‑acting.

The combination harnesses the potent Gram‑negative spectrum of aztreonam while protecting it from degradation by β‑lactamases that would otherwise inactivate it.

---

2. Why combine them?

1. Broad coverage of carbapenem‑resistant Gram‑negative organisms – the inhibitor restores aztreonam’s activity against strains producing carbapenemases (e.g., KPC, NDM, OXA‑48) that usually resist other β‑lactams.
2. Preserves activity against Gram‑positive and anaerobic bacteria – aztreonam alone is ineffective against Gram‑positives; the addition of avibactam does not confer this spectrum but removes the need for a separate anti‑Gram‑positive agent in many infections.
3. Reduced toxicity – both agents are generally well tolerated; the combination limits the use of carbapenems, lowering the risk of selecting for carbapenem‑resistant organisms.

---

3. Indications (as of 2024)

• Hospital‑acquired and ventilator‑associated pneumonia (HAP/VAP) caused by carbapenem‑resistant, β‑lactamase‑producing Gram‑negative bacteria, including:
  • Klebsiella pneumoniae (KPC, NDM, OXA‑48)
  • Acinetobacter baumannii (carbapenemase‑producing)
  • Pseudomonas aeruginosa (carbapenem‑resistant)
• Intra‑abdominal infections (including peritonitis) due to carbapenem‑resistant Gram‑negative organisms.
• Urinary tract infections (UTIs) with multidrug‑resistant Gram‑negative pathogens where alternative options are limited.
• Skin and soft‑tissue infections of bacterial etiology with carbapenem‑resistant organisms (off‑label in some regions).

Note: In many jurisdictions, the drug is approved only for severe, hospital‑acquired infections; its use in uncomplicated infections is off‑label and should be reserved for cases with confirmed susceptibility.

---

4. Dosing (adult)

Indication	Dose	Administration	Duration (typical)
HAP/VAP	2 g aztreonam / 500 mg avibactam	IV infusion over 60 min	7–14 days (adjust based on response)
Intra‑abdominal infection	2 g / 500 mg	IV	7–10 days
UTI (severe)	2 g / 500 mg	IV	7–14 days
Renal adjustment: Reduce total daily dose by ~30 % in patients with CrCl 30–59 mL/min; for CrCl <30 mL/min, use 1 g/250 mg q12h or 1 g/250 mg q8h, depending on infection severity.
Hepatic impairment: No dose adjustment needed for mild–moderate liver disease.

Infusion: Typically 1 g/250 mg IV over 30 min, repeated q12h (two doses per day) for most indications. In patients with severe infections or high bacterial burden, continuous infusion (q24h) may be considered.

---

5. Pharmacokinetics

Property	Aztreonam	Avibactam
Half‑life	~1 h (renal)	~0.7 h (renal)
Volume of distribution	15 L	11 L
Protein binding	20–25 %	10 %
Metabolism	Primarily renal excretion (≈ 90 %)	Renal excretion (≈ 80 %)
C_max (standard dose)	~6 µg/mL	~2 µg/mL

Because both components are largely renally cleared, dose adjustment is required in renal impairment; no major drug‑drug interactions are reported beyond the usual renal clearance concerns.

---

6. Spectrum of activity

Organism	Likely susceptible	Notes
Klebsiella pneumoniae (KPC, NDM, OXA‑48)	Susceptible	Restores activity lost to carbapenemases.
Enterobacter cloacae spp.	Susceptible	Many AmpC producers inhibited.
Pseudomonas aeruginosa (carbapenem‑resistant)	Variable	Generally active if no non‑β‑lactam resistance mechanisms (e.g., efflux, porin loss).
Acinetobacter baumannii (carbapenemase‑producing)	Susceptible	Depends on the presence of non‑β‑lactam resistance (e.g., carbapenem‑resistance via efflux).
Escherichia coli	Susceptible (if β‑lactamase‑producing)	Not effective against ESBL alone unless carbapenemase is present.
Gram‑positive cocci	Resistant	No activity.
Anaerobes	Resistant	Not covered.

---

7. Adverse events

• Common: Nausea, vomiting, diarrhea, headache, rash, mild infusion‑related reactions.
• Infusion reactions: Rare (anaphylaxis, hypotension). Premedicate with antihistamine in patients with history of reactions.
• Renal: No significant nephrotoxicity reported beyond the usual risk with high doses of β‑lactams; monitor CrCl regularly.
• Hepatic: Transaminase elevations rare; monitor liver enzymes in patients with pre‑existing hepatic disease.
• QT prolongation: No clinically relevant effect reported.

---

8. Resistance & stewardship

• Mechanisms: Loss of porin channels, efflux pumps, or mutations in PBPs can confer resistance even with avibactam present.
• Cross‑resistance: Some strains resistant to other β‑lactam/β‑lactamase inhibitor combinations (e.g., ceftazidime/avibactam) may still be susceptible to aztreonam/avibactam if the resistance is driven by metallo‑β‑lactamases (e.g., NDM) that avibactam cannot inhibit; however, aztreonam alone is stable to such enzymes.
• Use in stewardship: Reserve for confirmed carbapenem‑resistant infections; perform susceptibility testing before use.

---

9. Practical tips for clinicians

1. Confirm susceptibility: Minimum inhibitory concentration (MIC) for aztreonam/avibactam should be ≤0.25 mg/L for most severe infections.
2. Check renal function: Adjust dose based on CrCl; avoid accumulation in patients with severe renal impairment unless dosing is properly reduced.
3. Monitor for drug reactions: Watch for infusion reactions, especially in patients with prior β‑lactam allergies.
4. Avoid unnecessary use: Use only when other agents (e.g., carbapenems, piperacillin/tazobactam) are ineffective or contraindicated.
5. Combination therapy: For highly resistant infections, consider adding a